Join our 9th Annual Biomarkers Congress and be part of a two day event that will cover the latest advances in biomarker discovery, development and verification; focusing on breakthrough technologies and case studies from leading pharmaceutical organisations. Held at Manchester United's Old Trafford on 25th & 26th February 2014 this prestigious event will attract over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions.
The 9th Annual Biomarkers Congress will cover the latest advances in biomarker discovery and verification, including multiplex platforms, nanotechnology platforms and multiple reaction monitoring. Our expert speakers will also discuss efforts to increase biomarker sensitivity and specificity through genomic analysis, systems biology approaches and better sample management. In the Companion Diagnostics stream, presentations will cover Rx/Dx co-development, methods to increase predictive significance and regulatory considerations.
To build on the clinical case studies shared at last year's event, we are pleased to introduce the co-located 'Biomarkers in Clinical Development Congress', focusing on the role of biomarkers in clinical decision making, drug efficacy prediction and clinical safety. Key decision makers in personalised medicine will complement these discussions with their insights into adaptive trial design, patient stratification and markers for improved treatment response.
This event is not to be missed. Previous years testimonials include:
"There were many great qualities to the congress; presentations, time allocated to speakers, venue and networking facilities. I thought that the conference programme was excellent." Senior Biosample Operations Manager, Roche
"The structure of talks and sessions, friendly faces and the help of the Oxford Global staff were the highlights of the event for me. Thank you for organising these two very informative days." Senior Scientist, AstraZeneca
Speakers of the 9th Annual Biomarkers Congress include:
- Mark Curran, VP Immunology Biomarkers, Janssen
- Richard Buller, VP & Head, Clinical Development, Oncology, Pfizer
- Khusru Asadullah, VP and Head of Global Biomarkers, Bayer HealthCare
- John Burkhardt, VP, Preclinical Safety, Abbvie
- Bob Clay, VP Global Regulatory Affairs, Oncology, Infection and Personalised Healthcare, AstraZeneca
- Yiu-Lian Fong, Executive Director, Companion Diagnostic Development, Novartis
- Amelia Warner, Director Clinical Pharmacogenomics, Merck
Taking place on 25th & 26th February 2014 at Manchester United's Old Trafford: http://www.biomarkers-congress.com/.
Contact Danielle Dalby at Oxford Global on firstname.lastname@example.org or call +44 (0)1865 248455 for the full agenda and prices for attendance.